A physician reported via a literature article pertaining to a retrospective chart review that a (b)(6) male received deflux (dextranomer microspheres/hyaluronic acid) injection into the submucosa of the urinary bladder as treatment for left grade 1 vesicoureteral reflux (vur).Additional medical history included vacterl association with a crossed ectopic solitary left kidney, febrile urinary tract infections (utis), and a diverticulum medial to the orifice.Concomitant medications were not provided.On an unk date, the pt received deflux, 2 x 0.6 ml (1.2 ml total) utilizing the subureteral transurethral injection technique (sting).Perioperative prophylaxis and antibiotic prophylaxis for four weeks was given.No symptoms occurred, but a routine ultrasound 6 weeks later showed mild to moderate hydroureteronephrosis.At that time, no specific treatment was initiated.In the following 3 months, the pt had two utis and hydroureteronephrosis persisted on ultrasound.An open ureterocystoneostomy (cohen) was performed.Postoperative ultrasound 4 and 22 months later showed markedly decreased hydronephrosis.The authors concluded that the incidence of ureteral obstruction complication was higher than previously reported in the literature.Report received from q-med.The company assessed the events as possibly related to deflux.
|